PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis.

PCSK9 atherosclerosis dyslipidemia immunization

Journal

Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257

Informations de publication

Date de publication:
2021
Historique:
received: 17 02 2021
accepted: 02 03 2021
entrez: 15 9 2021
pubmed: 16 9 2021
medline: 16 9 2021
Statut: epublish

Résumé

The aim of the study was to study a nanoliposomal anti-PCSK9 vaccine as a novel approach for cholesterol lowering via PCSK9 inhibition. An immunogenic peptide construct termed immunogenic fused PCSK9-tetanus (IFPT) was displayed on the surface of liposome nanoparticles (L-IFPT) and mixed into alum adjuvant (L-IFPTA+). The manufactured vaccine formulations IFPT, L-IFPT, L-IFPTA+, IFPTA+, and free nanoliposomes were subcutaneously injected four times with bi-weekly intervals in C57BL/6 mice on a severe atherogenic protocol. Among the formulations, L-IFPTA+ vaccine was found to elicit the highest IgG response against PCSK9 peptide. The induced PCSK9 antibodies inhibited PCSK9-LDLR interaction through binding to PCSK9 in vaccinated mice. Liver low-density lipoprotein receptor (LDLR) protein was increased in vaccinated mice. L-IFPTA+, L-IFPT and IFPTA+ vaccines reduced total cholesterol by up to -38.13 ±3.8% ( L-IFPTA+ vaccine can induce long-lasting, functional and safe PCSK9-specific antibodies in hypercholesterolemic C57BL/6 mice, providing a long-term protective impact on dyslipidemia and atherosclerosis.

Identifiants

pubmed: 34522266
doi: 10.5114/aoms/133885
pii: 133885
pmc: PMC8425258
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1365-1377

Informations de copyright

Copyright: © 2021 Termedia & Banach.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Circ Res. 2015 Sep 25;117(8):731-41
pubmed: 26228031
Physiol Rev. 2006 Apr;86(2):515-81
pubmed: 16601268
Ann Intern Med. 1964 Nov;61:888-99
pubmed: 14233810
J Vasc Surg. 2002 Mar;35(3):554-62
pubmed: 11877706
Nature. 2013 Apr 11;496(7444):152-5
pubmed: 23579660
Atherosclerosis. 2019 Apr;283:69-78
pubmed: 30797988
BMC Med. 2019 Dec 10;17(1):223
pubmed: 31818299
Nat Rev Dis Primers. 2019 Aug 16;5(1):56
pubmed: 31420554
Int J Biol Sci. 2012;8(3):310-27
pubmed: 22355267
JAMA Cardiol. 2017 May 1;2(5):547-555
pubmed: 28291866
Lab Anim. 1997 Jan;31(1):1-32
pubmed: 9121105
Am J Pathol. 1996 Aug;149(2):359-66
pubmed: 8701976
N Engl J Med. 2015 Apr 16;372(16):1500-9
pubmed: 25773607
J Am Coll Cardiol. 2017 Feb 7;69(5):471-482
pubmed: 28153102
Curr Atheroscler Rep. 2013 Jan;15(1):291
pubmed: 23225173
J Cell Physiol. 2018 Jul;233(7):5189-5199
pubmed: 29215747
Curr Opin Lipidol. 2016 Aug;27(4):345-50
pubmed: 27389630
Int Immunol. 2004 Mar;16(3):501-8
pubmed: 14978023
Curr Cardiol Rep. 2013 Mar;15(3):345
pubmed: 23338726
N Engl J Med. 2015 Apr 16;372(16):1489-99
pubmed: 25773378
Circulation. 2001 May 29;103(21):2610-6
pubmed: 11382732
Int Heart J. 2014;55(2):96-100
pubmed: 24632960
Clin Cancer Res. 2001 Oct;7(10):3012-24
pubmed: 11595689
Nat Rev Drug Discov. 2004 Jan;3(1):81-8
pubmed: 14666113
JAMA. 2016 Dec 13;316(22):2373-2384
pubmed: 27846344
Postgrad Med J. 2005 Dec;81(962):746-52
pubmed: 16344296
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
Lancet. 1994 Nov 19;344(8934):1383-9
pubmed: 7968073
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Lab Anim. 1996 Oct;30(4):293-316
pubmed: 8938617
J Lipid Res. 2012 Aug;53(8):1654-61
pubmed: 22611251
Circ Res. 2016 Feb 19;118(4):535-46
pubmed: 26892956
Eur Heart J. 2017 Aug 21;38(32):2499-2507
pubmed: 28637178
J Lipid Res. 1983 Sep;24(9):1210-28
pubmed: 6631247
PLoS One. 2014 Dec 04;9(12):e114469
pubmed: 25474576
Cardiovasc Drugs Ther. 2013 Dec;27(6):559-67
pubmed: 23913122
Atherosclerosis. 2013 May;228(1):18-28
pubmed: 23466067
Sci Rep. 2017 Oct 2;7(1):12534
pubmed: 28970592
Circulation. 2001 Jul 10;104(2):197-202
pubmed: 11447086
Atherosclerosis. 2018 Nov;278:190-196
pubmed: 30296724
J Cardiovasc Pharmacol. 2017 Nov;70(5):339-352
pubmed: 28777256
Circulation. 1994 May;89(5):2462-78
pubmed: 8181179
JAMA. 2011 Apr 13;305(14):1460-8
pubmed: 21486979

Auteurs

Amir Abbas Momtazi-Borojeni (AA)

Nanotechnology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Mahmoud Reza Jaafari (MR)

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohammad Afshar (M)

Department of Anatomy, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Maciej Banach (M)

Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland.
Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.

Amirhossein Sahebkar (A)

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Classifications MeSH